Search Results - "HEZODE, Christophe"

Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice by Hezode, Christophe

“…Effective management of adverse events (AEs) is important to prevent treatment discontinuation and optimize hepatitis C virus infection eradication rates. The…”
Get full text

Antiviral strategies in hepatitis C virus infection by Sarrazin, Christoph, Hézode, Christophe, Zeuzem, Stefan, Pawlotsky, Jean-Michel

“…Summary Resolution of the three-dimensional structures of several hepatitis C virus (HCV) proteins, together with the development of replicative cell culture…”
Get full text

Why I do not treat patients for mild disease by Hézode, Christophe

“…The short‐term prognosis of patients with chronic hepatitis C and mild disease is excellent. Monitoring of the progression of fibrosis is easy to perform with…”
Get full text

Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: Finite treatment duration unlikely by Chevaliez, Stéphane, Hézode, Christophe, Bahrami, Stéphane, Grare, Marion, Pawlotsky, Jean-Michel

“…Background & Aims Information regarding long-term HBsAg kinetics during treatment with nucleoside/nucleotide analogues is limited. The aim of the present study…”
Get full text

ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis by Poordad, Fred, Hezode, Christophe, Trinh, Roger, Kowdley, Kris V, Zeuzem, Stefan, Agarwal, Kosh, Shiffman, Mitchell L, Wedemeyer, Heiner, Berg, Thomas, Yoshida, Eric M, Forns, Xavier, Lovell, Sandra S, Da Silva-Tillmann, Barbara, Collins, Christine A, Campbell, Andrew L, Podsadecki, Thomas, Bernstein, Barry

“…In patients with HCV genotype 1 infection and cirrhosis, the rate of sustained virologic response was 92% with three new antiviral agents plus ribavirin for 12…”
Get full text

Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+) by Leroy, Vincent, Angus, Peter, Bronowicki, Jean‐Pierre, Dore, Gregory J., Hezode, Christophe, Pianko, Stephen, Pol, Stanislas, Stuart, Katherine, Tse, Edmund, McPhee, Fiona, Bhore, Rafia, Jimenez‐Exposito, Maria Jesus, Thompson, Alexander J.

“…Patients with hepatitis C virus (HCV) genotype 3 infection, especially those with advanced liver disease, are a challenging population in urgent need of…”
Get full text

Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients by Pol, Stanislas, Bourliere, Marc, Lucier, Sandy, Hezode, Christophe, Dorival, Céline, Larrey, Dominique, Bronowicki, Jean-Pierre, Ledinghen, Victor D.E, Zoulim, Fabien, Tran, Albert, Metivier, Sophie, Zarski, Jean-Pierre, Samuel, Didier, Guyader, Dominique, Marcellin, Patrick, Minello, Anne, Alric, Laurent, Thabut, Dominique, Chazouilleres, Olivier, Riachi, Ghassan, Bourcier, Valérie, Mathurin, Philippe, Loustaud-Ratti, Véronique, D’Alteroche, Louis, Fouchard-Hubert, Isabelle, Habersetzer, François, Causse, Xavier, Geist, Claire, Rosa, Isabelle, Gournay, Jérôme, Saillard, Eric, Billaud, Eric, Petrov-Sanchez, Ventzislava, Diallo, Alpha, Fontaine, Hélène, Carrat, Fabrice

“…Graphical abstract…”
Get full text

Management of anaemia and other treatment complications by Hézode, Christophe

“…Abstract Antiviral treatment for hepatitis C virus infection has dramatically changed with the advent of triple therapy including telaprevir or boceprevir,…”
Get full text

Efficacy and Safety of Sofosbuvir plus Daclatasvir for Treatment of HCV-associated Cryoglobulinemia Vasculitis by Saadoun, David, Pol, Stanislas, Ferfar, Yasmina, Alric, Laurent, Hezode, Christophe, Si Ahmed, Si Nafa, de Saint Martin, Luc, Comarmond, Cloé, Bouyer, Anne Sophie, Musset, Lucile, Poynard, Thierry, Resche Rigon, Matthieu, Cacoub, Patrice

“…Abstract Circulating mixed cryoglobulins are detected in 40%–60% of patients with hepatitis C virus (HCV) infection, and overt cryoglobulinemia vasculitis…”
Get full text

Evaluation of the Xpert HBV Viral Load for hepatitis B virus molecular testing by Poiteau, Lila, Wlassow, Mélanie, Hézode, Christophe, Pawlotsky, Jean-Michel, Chevaliez, Stéphane

“…•Detection of HBV helps guide treatment and assess risk of complications.•Xpert HBV Viral Load assay runs on a fully automated, continuous, random-access…”
Get full text

Oral combination therapy: Future hepatitis C virus treatment? by Hézode, Christophe

“…COMMENTARY ON: Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1):…”
Get full text

Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890 by Hézode, Christophe, Fontaine, Hélène, Dorival, Céline, Larrey, Dominique, Zoulim, Fabien, Canva, Valérie, de Ledinghen, Victor, Poynard, Thierry, Samuel, Didier, Bourlière, Marc, Zarski, Jean-Pierre, Raabe, Jean-Jacques, Alric, Laurent, Marcellin, Patrick, Riachi, Ghassan, Bernard, Pierre-Henri, Loustaud-Ratti, Véronique, Métivier, Sophie, Tran, Albert, Serfaty, Lawrence, Abergel, Armand, Causse, Xavier, Di Martino, Vincent, Guyader, Dominique, Lucidarme, Damien, Grando-Lemaire, Véronique, Hillon, Patrick, Feray, Cyrille, Dao, Thong, Cacoub, Patrice, Rosa, Isabelle, Attali, Pierre, Petrov-Sanchez, Ventzislava, Barthe, Yoann, Pawlotsky, Jean-Michel, Pol, Stanislas, Carrat, Fabrice, Bronowicki, Jean-Pierre

“…Background & Aims In phase III trials, the safety profile of triple therapy (pegylated interferon/ribavirin with boceprevir or telaprevir) seems to be similar…”
Get full text

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial by Sulkowski, Mark, Dr Prof, Hezode, Christophe, Prof, Gerstoft, Jan, Prof, Vierling, John M, Prof, Mallolas, Josep, MD PhD, Pol, Stanislas, Prof, Kugelmas, Marcelo, MD, Murillo, Abel, MD, Weis, Nina, PhD, Nahass, Ronald, Prof, Shibolet, Oren, MD, Serfaty, Lawrence, MD, Bourliere, Marc, MD, DeJesus, Edwin, MD, Zuckerman, Eli, Prof, Dutko, Frank, PhD, Shaughnessy, Melissa, MS, Hwang, Peggy, PhD, Howe, Anita Y M, PhD, Wahl, Janice, MD, Robertson, Michael, MD, Barr, Eliav, MD, Haber, Barbara, MD

“…Summary Background Both hepatitis C virus (HCV) mono-infected and HIV/HCV co-infected patients are in need of safe, effective, all-oral HCV regimens. In a…”
Get full text

Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis by Hézode, Christophe, Fontaine, Helene, Dorival, Celine, Zoulim, Fabien, Larrey, Dominique, Canva, Valerie, De Ledinghen, Victor, Poynard, Thierry, Samuel, Didier, Bourliere, Marc, Alric, Laurent, Raabe, Jean–Jacques, Zarski, Jean–Pierre, Marcellin, Patrick, Riachi, Ghassan, Bernard, Pierre–Henri, Loustaud–Ratti, Veronique, Chazouilleres, Olivier, Abergel, Armand, Guyader, Dominique, Metivier, Sophie, Tran, Albert, Di Martino, Vincent, Causse, Xavier, Dao, Thong, Lucidarme, Damien, Portal, Isabelle, Cacoub, Patrice, Gournay, Jerome, Grando–Lemaire, Veronique, Hillon, Patrick, Attali, Pierre, Fontanges, Thierry, Rosa, Isabelle, Petrov–Sanchez, Ventzislava, Barthe, Yoann, Pawlotsky, Jean–Michel, Pol, Stanislas, Carrat, Fabrice, Bronowicki, Jean–Pierre

“…Background & Aims We investigated the effectiveness of the protease inhibitors peginterferon and ribavirin in treatment-experienced patients with hepatitis C…”
Get full text

Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS) by Bourlière, Marc, Dr, Bronowicki, Jean-Pierre, MD, de Ledinghen, Victor, MD, Hézode, Christophe, MD, Zoulim, Fabien, MD, Mathurin, Philippe, MD, Tran, Albert, MD, Larrey, Dominique G, MD, Ratziu, Vlad, MD, Alric, Laurent, MD, Hyland, Robert H, DPhil, Jiang, Deyuan, PhD, Doehle, Brian, PhD, Pang, Phillip S, MD, Symonds, William T, PharmD, Subramanian, G Mani, MD, McHutchison, John G, MD, Marcellin, Patrick, MD, Habersetzer, François, MD, Guyader, Dominique, MD, Grangé, Jean-Didier, MD, Loustaud-Ratti, Véronique, MD, Serfaty, Lawrence, MD, Metivier, Sophie, MD, Leroy, Vincent, MD, Abergel, Armand, MD, Pol, Stanislas, MD

“…Summary Background Patients with cirrhosis resulting from chronic hepatitis C virus (HCV) infection are at risk of life-threatening complications, but…”
Get full text

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial by Pol, Stanislas, Dr Prof, Ghalib, Reem H, Prof, Rustgi, Vinod K, Prof, Martorell, Claudia, Prof, Everson, Greg T, Prof, Tatum, Harvey A, Prof, Hézode, Christophe, Prof, Lim, Joseph K, Prof, Bronowicki, Jean-Pierre, Prof, Abrams, Gary A, Prof, Bräu, Norbert, Prof, Morris, David W, Prof, Thuluvath, Paul J, Prof, Reindollar, Robert W, Prof, Yin, Philip D, MD, Diva, Ulysses, PhD, Hindes, Robert, MD, McPhee, Fiona, PhD, Hernandez, Dennis, PhD, Wind-Rotolo, Megan, PhD, Hughes, Eric A, MD, Schnittman, Steven, MD

“…Summary Background Several direct-acting antivirals for chronic hepatitis C virus (HCV) infection are available, but they are limited by tolerability and…”
Get full text

Performance of rapid diagnostic tests for hepatitis B surface antigen detection in serum or plasma by Chevaliez, Stéphane, Roudot-Thoraval, Françoise, Hézode, Christophe, Pawlotsky, Jean-Michel, Njouom, Richard

“…Hepatitis B surface antigen (HBsAg) is a key marker for screening and laboratory diagnosis of HBV infection. Rapid diagnostic tests (RDTs) represent promising…”
Get full text

French Patients with Hepatitis C Treated with Direct-Acting Antiviral Combinations: The Effect on Patient-Reported Outcomes by Cacoub, Patrice, Bourliere, Marc, Asselah, Tarik, De Ledinghen, Victor, Mathurin, Philippe, Hézode, Christophe, Henry, Linda, Stepanova, Maria, Younossi, Zobair M.

“…In addition to high efficacy, new anti–hepatitis C virus (HCV) regimens improve patient-reported outcomes (PROs), which must be considered by policymakers in…”
Get full text

Patient with decompensated hepatitis C virus–related cirrhosis delisted for liver transplantation after successful sofosbuvir‐based treatment by Ruiz, Isaac, Feray, Cyrille, Pawlotsky, Jean‐Michel, Hézode, Christophe

Get full text

The New Aptima HBV Quant Real-Time TMA Assay Accurately Quantifies Hepatitis B Virus DNA from Genotypes A to F by Chevaliez, Stéphane, Dauvillier, Claude, Dubernet, Fabienne, Poveda, Jean-Dominique, Laperche, Syria, Hézode, Christophe, Pawlotsky, Jean-Michel

“…Sensitive and accurate hepatitis B virus (HBV) DNA detection and quantification are essential to diagnose HBV infection, establish the prognosis of HBV-related…”
Get full text